PCA
ABBV icon

Pallas Capital Advisors’s AbbVie ABBV Stock Holding History

Pallas Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.56M Buy
26,085
+644
+3% +$139K 0.2% 87
2026
Q1 		$5.53M Sell
25,441
-2,588
-9% -$574K 0.21% 95
2025
Q4 		$6.4M Sell
28,029
-2,261
-7% -$515K 0.21% 85
2025
Q3 		$7.01M Sell
30,290
-1,019
-3% -$208K 0.26% 79
2025
Q2 		$5.81M Buy
31,309
+739
+2% +$137K 0.22% 83
2025
Q1 		$6.4M Buy
30,570
+706
+2% +$137K 0.27% 77
2024
Q4 		$5.31M Sell
29,864
-236
-0.8% -$43.4K 0.23% 89
2024
Q3 		$5.71M Sell
30,100
-291
-1% -$54.3K 0.24% 88
2024
Q2 		$5.2M Buy
30,391
+185
+0.6% +$30.6K 0.23% 93
2024
Q1 		$5.5M Buy
30,206
+3,374
+13% +$581K 0.23% 87
2023
Q4 		$4.16M Sell
26,832
-3,093
-10% -$451K 0.22% 93
2023
Q3 		$4.25M Buy
29,925
+6,729
+29% +$988K 0.26% 80
2023
Q2 		$3.13M Buy
23,196
+17,337
+296% +$2.54M 0.14% 93
2023
Q1 		$961K Buy
5,859
+2,305
+65% +$352K 0.09% 150
2022
Q4 		$532K Buy
3,554
+28
+0.8% +$4.29K 0.05% 177
2022
Q3 		$509K Buy
3,526
+31
+0.9% +$4.45K 0.06% 166
2022
Q2 		$519K Sell
3,495
-178
-5% -$27.2K 0.07% 143
2022
Q1 		$596K Buy
3,673
+1,202
+49% +$175K 0.08% 145
2021
Q4 		$326K Sell
2,471
-416
-14% -$49.1K 0.04% 243
2021
Q3 		$339K Sell
2,887
-288
-9% -$32.9K 0.04% 290
2021
Q2 		$365K Buy
3,175
+1,307
+70% +$147K 0.05% 229
2021
Q1 		$217K Buy
+1,868
New +$200K 0.05% 172

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Pallas Capital Advisors's ABBV Position: Q2 2026 in Review

Pallas Capital Advisors increased its AbbVie (ABBV) stake by 2.5% in Q2 2026, buying an estimated $139K and bringing the position to 26,085 shares worth $6.56M. The position accounts for 0.2% of the portfolio, ranked #87.

Pallas Capital Advisors first reported a position in ABBV in Q1 2021 and has held it in 22 quarters since. The position peaked at $7.01M in Q3 2025. 4,225 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Pallas Capital Advisors held 26,085 shares of AbbVie worth $6.56M as of Q2 2026.
  • Pallas Capital Advisors bought 644 AbbVie shares in Q2 2026, an estimated $139K.
  • AbbVie made up 0.2% of Pallas Capital Advisors's portfolio in Q2 2026, its #87 holding.
  • Pallas Capital Advisors first reported a position in AbbVie in Q1 2021 and has held it in 22 quarters since.
  • Pallas Capital Advisors's AbbVie position peaked at $7.01M in Q3 2025.
  • 4,225 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.